New insider activity at Amneal Pharmaceuticals ( (AMRX) ) has taken place on June 12, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Gautam Patel has recently sold 56,426 shares of Amneal Pharmaceuticals stock, amounting to a total transaction value of $452,536.
Recent Updates on AMRX stock
Amneal Pharmaceuticals has recently experienced significant developments, impacting its stock. The U.S. FDA approved the company’s prednisolone acetate ophthalmic suspension, highlighting its R&D capabilities and manufacturing strength. Additionally, Amneal announced the FDA approval of Brekiya injection, a novel autoinjector for migraine and cluster headaches, offering a new therapeutic option for patients. These approvals demonstrate Amneal’s expanding product pipeline, which is expected to drive growth, particularly in its generics segment. However, the company is also recalling Sulfamethoxazole/Trimethoprim tablets due to microbial contamination concerns. These mixed developments have influenced market perceptions, with analysts like Goldman Sachs initiating coverage with a positive outlook based on the company’s strong product pipeline and growth potential.
Spark’s Take on AMRX Stock
According to Spark, TipRanks’ AI Analyst, AMRX is a Neutral.
Amneal Pharmaceuticals’ stock score is driven by a strong earnings call performance highlighting growth in key areas, offset by financial challenges such as high leverage and a negative P/E ratio. Technical analysis shows a neutral trend, while valuation concerns persist due to ongoing losses.
To see Spark’s full report on AMRX stock, click here.
More about Amneal Pharmaceuticals
YTD Price Performance: 0.26%
Average Trading Volume: 1,920,414
Technical Sentiment Signal: Hold
Current Market Cap: $2.45B